odmj

OncoDaily Medical Journal

ODMJ

3067-6444

OncoDaily Medical Journal

7730

10.69690/ODMJ-012-0826-7730

Systematic Reviews & Meta Analysis

Chronic illness trajectory of patients with multiple myeloma derived from health-related quality of life data – an integrative review

https://orcid.org/0000-0003-3169-1812

Naegele

Matthias

Department of Medical Oncology and Haematology at the Cantonal Hospital St. Gallen/HOCH Health Ostschweiz, St. Gallen, Switzerland matthias.hellberg-naegele@h-och.ch

Department of Medical Oncology and Haematology at the Cantonal Hospital St. Gallen/HOCH Health Ostschweiz, St. Gallen, Switzerland

Neumann

Martin

University Heart Center Freiburg, Bad Krozingen, Germany

02 08 2026

ODMJ-012-0826-7730

2026

OncoDaily Medical Journal

chronic illness trajectory health related quality of life Multiple Myeloma

production-ready-file-url

Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33(3):225-36.

Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670-7.

Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385(9983):2197-208.

Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-20.

Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464-77.

Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017;281(4):365-82.

Ricciuti G, Falcone A, Cascavilla N, Martinelli G, Cerchione C. Autologous stem cell transplantation in multiple myeloma. Panminerva Med. 2020;62(4):220-4.

Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer. 2016;16:427.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9.

Corbin JM. The Corbin and Strauss chronic illness trajectory model: an update. Sch Inq Nurs Pract. 1998;12(1):33-41.

Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-5.

Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546-53.

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.

Hong QN, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, et al. Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study. J Clin Epidemiol. 2019;111:49-59.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.

Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer. 2019;107:153-63.

Mian H, Mian OS, Rochwerg B, Foley R, Wildes TM. Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis. J Geriatr Oncol. 2020;11(1):93-9.

Ricciuti G, Falcone A, Cascavilla N, Martinelli G, Cerchione C. Autologous stem cell transplantation in multiple myeloma. Panminerva Med. 2020;62(4):220-4.

Fleischer A, Zapf L, Allgaier J, Jordan K, Gelbrich G, Pryss R, et al. A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials. J Cancer Res Clin Oncol. 2023.

Kirkpatrick S, Campbell K, Harding S. A survey of quality-of-life tools used in the routine care of patients with multiple myeloma. Br J Nurs. 2023;32(5):S10-4.

Park J, Look KA. Health care expenditure burden of cancer care in the United States. Inquiry. 2019;56:46958019880696.

Seefat MR, Cucchi DGJ, Dirven S, Groen K, Zweegman S, Blommestein HM. A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma. Cancers (Basel). 2021;13(22):5606.

Neumann M. Beratungsbedürfnisse im Krankheitsverlauf aus Sicht von an einem Multiplen Myelom erkrankten Menschen [unpublished manuscript]. Freiburg: Katholische Hochschule; 2019.

Delforge M, Shah N, San-Miguel JF, Braverman J, Dhanda DS, Shi L, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6(4):1309-18.

Nielsen LK, Stege C, Lissenberg-Witte B, van der Holt B, Mellqvist UH, Salomo M, et al. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica. 2020;105(6):1650-9.

Bladé J, Calleja MÁ, Lahuerta JJ, Poveda JL, de Paz HD, Lizán L. Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project. BMJ Open. 2018;8(2):e018850.

Salek S, Ionova T, Oliva EN, Andreas M, Skoetz N, Kreuzberger N, et al. The reporting, use, and validity of patient-reported outcomes in multiple myeloma in clinical trials: a systematic literature review. Cancers (Basel). 2022;14(23):6007.

Nielsen LK, Jarden M, Andersen CL, Frederiksen H, Abildgaard N. A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol. 2017;99(1):3-17.

Fischer J, Knop S, Danhof S, Einsele H, Keller D, Löffler C. The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study. BMC Cancer. 2022;22(1):1032.

O’Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222-30.

Abonour R, Wagner L, Durie BGM, Jagannath S, Narang M, Terebelo HR, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect MM Registry. Ann Hematol. 2018;97(12):2425-36.

Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, et al. Patient-reported outcome results from the open-label, randomized phase III Myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma. J Clin Oncol. 2019;37(19):1617-28.

Despiégel N, Touboul C, Flinois A, Saba G, Suzan F, Gonzalez-McQuire S, et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk. 2019;19(1):e13-28.

Dimopoulos MA, Delforge M, Hájek R, Kropff M, Petrucci MT, Lewis P, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98(5):784-8.

Korde N, Tavitian E, Mastey D, Lengfellner J, Hevroni G, Zarski A, et al. Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study. EClinicalMedicine. 2023;57:101854.

Maschio M, Zarabla A, Maialetti A, Marchesi F, Giannarelli D, Gumenyuk S, et al. The effect of docosahexaenoic acid and α-lipoic acid as prevention of bortezomib-related neurotoxicity in patients with multiple myeloma. Integr Cancer Ther. 2019;18:1534735419888584.

Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015;100(6):826-33.

Nielsen L, Klausen T, Kristensen I, Frølund U, Andersen N, Andersen C, et al. Clarithromycin added to the VCD regimen causes reduced health-related quality of life in multiple myeloma patients. HemaSphere. 2018;2(S1):659-60.

Asrar MM, Lad DP, Bansal D, Prinja S, Khadwal A, Prakash G, et al. Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting. Leuk Lymphoma. 2021;62(13):3271-7.

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, et al. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial. Eur J Haematol. 2020;104(5):443-58.

Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, et al. Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial. J Clin Oncol. 2021;39(3):227-37.

Richardson PG, Jacobus SJ, Weller E, Hassoun H, Lonial S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): the phase 3 DETERMINATION trial. J Clin Oncol. 2022;40(17 Suppl):LBA4.

Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol. 2013;31(2):247-55.

Roussel M, Hebraud B, Hulin C, Perrot A, Caillot D, Stoppa AM, et al. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2020;61(6):1323-33.

Royle KL, Gregory WM, Cairns DA, Bell SE, Cook G, Owen RG, et al. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. Br J Haematol. 2018;182(6):816-29.

Knop S, Mateos MV, Dimopoulos MA, Suzuki K, Jakubowiak A, Doyen C, et al. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer. 2021;21(1):659.

Etto LY, Morelli V, Silva V, Hungria V, Ciconelli R, Almeida M, et al. Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients. Clinics (Sao Paulo). 2011;66(11):1855-9.

Verelst SGR, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AHM, Wittebol S, et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol. 2011;90(12):1427-39.